Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily f...
Saved in:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/25422 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.25422 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.254222018-09-07T15:54:37Z Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand Douglas S. Walsh Sornchai Looareesuwan Polrat Wilairatana D. Gray Heppner Douglas B. Tang Thomas G. Brewer Watcharee Chokejindachai Parnpen Viriyavejakul Dennis E. Kyle Wilbur K. Milhous Brian G. Schuster John Horton David J. Braitman Ralf P. Brueckner Mahidol University Walter Reed Army Institute of Research U.S. Army Medical Materiel Development Activity GlaxoSmithKline plc. Immunology and Microbiology Medicine WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse. 2018-09-07T08:50:35Z 2018-09-07T08:50:35Z 1999-12-01 Article Journal of Infectious Diseases. Vol.180, No.4 (1999), 1282-1287 10.1086/315034 00221899 2-s2.0-0033383602 https://repository.li.mahidol.ac.th/handle/123456789/25422 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033383602&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Immunology and Microbiology Medicine |
spellingShingle |
Immunology and Microbiology Medicine Douglas S. Walsh Sornchai Looareesuwan Polrat Wilairatana D. Gray Heppner Douglas B. Tang Thomas G. Brewer Watcharee Chokejindachai Parnpen Viriyavejakul Dennis E. Kyle Wilbur K. Milhous Brian G. Schuster John Horton David J. Braitman Ralf P. Brueckner Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand |
description |
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse. |
author2 |
Mahidol University |
author_facet |
Mahidol University Douglas S. Walsh Sornchai Looareesuwan Polrat Wilairatana D. Gray Heppner Douglas B. Tang Thomas G. Brewer Watcharee Chokejindachai Parnpen Viriyavejakul Dennis E. Kyle Wilbur K. Milhous Brian G. Schuster John Horton David J. Braitman Ralf P. Brueckner |
format |
Article |
author |
Douglas S. Walsh Sornchai Looareesuwan Polrat Wilairatana D. Gray Heppner Douglas B. Tang Thomas G. Brewer Watcharee Chokejindachai Parnpen Viriyavejakul Dennis E. Kyle Wilbur K. Milhous Brian G. Schuster John Horton David J. Braitman Ralf P. Brueckner |
author_sort |
Douglas S. Walsh |
title |
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand |
title_short |
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand |
title_full |
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand |
title_fullStr |
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand |
title_full_unstemmed |
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand |
title_sort |
randomized dose-ranging study of the safety and efficacy of wr 238605 (tafenoquine) in the prevention of relapse of plasmodium vivax malaria in thailand |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/25422 |
_version_ |
1763494637716111360 |